Last Updated: November 8, 2026

Details for Patent: RE50642

« Back to Dashboard


Which drugs does patent RE50642 protect, and when does it expire?

Patent RE50642 protects ERLEADA and is included in one NDA.

This patent has seventy-two patent family members in thirty-five countries.

Summary for Patent: RE50642
Title:Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Abstract:Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
Inventor(s):Isan Chen
Assignee: Aragon Pharmaceuticals Inc
Application Number:US17/896,658
Patent Claim Types:
see list of patent claims		Use; Delivery;

Drugs Protected by US Patent RE50642

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 AB RX Yes No RE50642 ⤷  Start Trial TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) BY DAILY ADMINISTRATION OF 180 MG OR 120 MG OF APALUTAMIDE TO PATIENTS RECEIVING A GONADOTROPIN-RELEASING HORMONE (GNRH) ANALOG ⤷  Start Trial
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-002 Feb 17, 2023 RX Yes Yes RE50642 ⤷  Start Trial TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) BY DAILY ADMINISTRATION OF 180 MG OR 120 MG OF APALUTAMIDE TO PATIENTS RECEIVING A GONADOTROPIN-RELEASING HORMONE (GNRH) ANALOG ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links